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Context/Objective: Hyperinsulinism with islet cell hyperplasia is a frequent complication, of un-
known cause, in hemolytic disease of the newborn, occurring in Rh(D)-positive infants of Rh-
isoimmunized Rh(D)-negative mothers, but not in infants with other hemolytic disorders. We
investigated thepossibility that trans-placentally acquiredanti-D Ig is the causeof both conditions.
Design: Monolayer cultures of human islet cells were exposed to sera from Rh-isoimmunized
mothers and newborns, where jaundice, hyperinsulinism, and hypoglycemia in the infant had
ensued. Parallel cultures with anti-D, specific anti-D monoclonal antibodies, normal human Ig (15
g/ml), and serum controls were also undertaken. Islet cell proliferation was determined by
[3H]thymidine incorporation. Insulin storage and chronic and acute insulin secretion to glucose
were analyzed by RIA. Rh(D) surface antigen expression was determined on islet cells by flow
cytometric analysis.
Results: Islet cell proliferation and insulin secretion were significantly greater in coculture with
test sera (P 0.01; n 8) and with anti-D (P 0.001; n 8), compared with either controls or Ig.
After 8 d of growth, the static incubation experiment showed a 3.5-fold response to glucose
stimulus in all sera. Rh(D) antigen expression was detected on the islet cell surface by flow cytom-
etry, and islet cell morphology was normal. Colocalization of the proliferation marker Ki67 with
insulin by immunofluorescent staining further indicated that Rh(D) antibody promoted islet growth.
Conclusions: The anti-Rh(D) islet cell proliferative effect generates neonatal hyperinsulinism in Rh
isoimmunization. Anti-Rh(D) may have application for islet cell proliferation in diabetes mellitus
treatment for Rh(D)-positive subjects. Further analysis is required. (J Clin Endocrinol Metab 93:
3560–3567, 2008)
Hyperinsulinism, due to fetal islet cell hyperplasia, is a com-plication in the newborn of Rh(D)-isoimmunized moth-
ers, but the basis for this is unknown. We suggest that this phe-
nomenon may be a consequence of trans-placentally acquired
anti-Rh(D) antibody, either alone or in combination with other
trophic influences. Our confirmation of this specific, growth-
promoting effect in vitro potentiates the identification and char-
acterization of a factor that may ultimately have therapeutic
application in the treatment of diabetes mellitus. This study in-
vestigated the in vitro growth-stimulating effect of commercially
available anti-D monoclonal antibodies and maternal sera, or
infant umbilical cord sera from subjects where maternal anti-D
antibody has crossed the placenta, upon human islet cells.
Hyperinsulinemia and hypoglycemia are recognized compli-
cations of erythroblastosis fetalis in newborns of Rh-isoimmu-
nized mothers (1, 2) and are associated with pancreatic islet cell
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hyperplasia, evident from postmortem findings from both fe-
tuses and newborns (3, 4). This phenomenon in hemolytic dis-
ease of the newborn (HDN) seems to be specific to Rh isoim-
munization and has been neither reported for other antibodies
responsible for cases of HDN, such as in ABO incompatibility,
nor observed with the nonimmune, hemolytic states, such as
hereditary spherocytosis or -thalassemia. Therefore, the mech-
anism of Rh-related induction of islet cell hyperplasia is unlikely
to be due to excess breakdown of fetal red cells and their by-
products, such as glutathione, as previously suggested (5).
In normal pregnancy, there is an immunological tolerance
betweenmotherand fetuswithprogressionof embryological and
fetal development controlled by the trophic effects of numerous
growth factors. These factors, in turn, interact with genetically
predetermined fetal influences that, when disrupted, may be re-
sponsible for excessive cell proliferation in one or more organ
systems, including the pancreatic islet cells with accompany-
ing hyperinsulinism (6). There have been reports of islet cell
proliferation after experimental pancreatic injury (7, 8), lay-
ing a foundation for possible strategies to promote pancreatic
regeneration.
In this study, we have investigated the possibility that Rh(D)
antibodymight exert such islet growth-promoting actions. Sam-
ples of serawere collected frommother and infant umbilical cord
blood at the time of delivery, when Rh(D) isoimmunization was
suspected.After confirmationof theoccurrenceofHDNthrough
transfer of maternal anti-D antibody across the placenta and
evidence of both hypoglycemia and hyperinsulinemia, these sera
samples were assessed, alone and in parallel with anti-D Ig or
anti-D monoclonal antibodies (9, 10), for their ability to stim-
ulate growth of human pancreatic islet cells. We have demon-
strated an augmented proliferation of islet -cells cultured in the
presence of anti-D antibody.
Patients and Methods
Collection of sera
After approval from theHuman Ethics Committee of the South East-
ern Sydney Area Health Service, subjects were identified and recruited.
Patients with medical conditions or on medications and those who had
labor induced artificially were excluded. A 10-ml sample of maternal
blood was collected in the week before onset of labor.
Serum 1 was collected from an Rh(D)-negative mother whose infant
was confirmed to be Rh(D) positive and direct antibody test (DAT)
positive was jaundiced and had both hypoglycemia and hyperinsulin-
emia. Serum 2 was collected from an Rh-negative mother whose infant
was confirmed to be Rh(D) positive and strongly DAT positive and was
jaundiced but had neither hypoglycemia nor hyperinsulinemia. Serum 3
was collected from an Rh(D)-negative, isoimmunized mother. Serum 4
was collected from the infant of serum 3 sample mother, and this infant
hadmoderately severe hyperinsulinism but profoundly severe hemolytic
disease. Normal human serumwas used as a control throughout (Prince
of Wales Hospital, Sydney, Australia). Sera were heat inactivated at 56
C for 30 min. Anti-D antibody was obtained from CSL Ltd. (Victoria,
Australia) and intraglobin F (normal human Ig) from MDA Pharma
(Sydney, Australia). Anti-D monoclonal antibodies BRAD-3, BRAD-5,
and FOG-1, were gifts from Belinda Kumpel, National Blood Service
(Bristol, UK).
Isolation and culture of islets
Ethics committee approval was obtained for the isolation of islets
from pancreases received from 22 Rh(D)-positive and six Rh(D)-nega-
tive brain-dead, beating-heart organ donors sent toWestmeadHospital,
New South Wales, and St. Vincent’s Institute of Medical Research, Vic-
toria. Islets were extracted from the whole pancreas by a modified Ed-
monton method, using an apheresis unit and density gradients (11). The
islets were cultured in Ham’s F10 media containing 6.1 mM glucose and
10% human serum for 24 h before transport at room temperature (RT)
to the University of Technology Sydney. Because the islet preparation
was 75–90% pure, the islets were centrifuged at 30 g for 5 min at RT
andresuspended inRPMI1640 (ThermoElectronAustralia,NoblePark,
Australia)mediumcontaining 5.5mMglucose plus normal human serum
(10%). After dithizone staining (12), the islets were handpicked and
cultured free-floating in the RPMI 1640medium for another 24 h before
monolayer culture. This procedure was performed on eight separate
occasions, providing samples for eight individual experiments. Two or
more samples from each batch of islets were used to assess viability,
using an acridine orange (0.06 g/ml)/ethidiumbromide (0.2 g/ml) vital
stain. The sample was then examined by fluorescence microscopy
using a band pass filter of wavelength 515–560 nm. Islets were used
only if viability after preparation was more than 95%.
The islets were transferred to 12-well tissue culture plates coated
with bovine corneal matrix (Bacto Laboratories Co., Liverpool, Aus-
tralia) (20 islets per well) and cultured in RPMI 1640 medium plus
normal human serum (10%). To prevent fibroblast overgrowth of the
cultures, 0.46 g/ml sodium ethylmercurithiosalicylate (thiomersal)
(Sigma-Aldrich Co., Castle Hill, Australia) was added 24 h after plat-
ing for 48 h. This has been previously reported (13) and shown in our
laboratory to prevent fibroblast contamination of primary islet cul-
tures while not exerting detrimental effects upon islet growth or func-
tion. After thiomersal treatment, islets were washed three times and
cultured in RPMI 1640 medium containing one of the sera listed
above. The cultures were maintained for another 8 d, with the media
changed every 2 d.
Proliferation assay
To the monolayer cultures treated with each of the sera and cultures
supplementedwithanti-D Ig (5–20g/ml), 15g intraglobinF,ormono-
clonal anti-D BRAD-3 (IgG3), BRAD-5 (IgG1), and FOG-1 (IgG1), 37
Mbq/ml of [3H]thymidinewas added to eachwell for 24h. Subsequently,
the cells were washed twice with ice-cold PBS and twice with ice-cold
10% trichloroacetic acid. The trichloroacetic acid-insoluble precipitate
was solubilizedwith 2%SDSandanalyzed (5min/vial) using a-counter
(Wallac 1470 distributed by Pfizer Inc., New York, NY).
Acute insulin secretion
After 8 d of culture in the sera and/or antibody-supplemented
media, monolayers were assessed for any acute response to a glucose
stimulus (16.7 mM or for glucose dose-response curves, 1.25–20mM),
as previously described (14). Cellular DNA content was analyzed by
fluorometry (15).
Expression of Rh(D) antigen on islet cells
The culture medium was removed from islet cells and the adherent
cells rinsed with PBS before incubation at 37 C for 10 min with a stan-
dardized and stabilized bromelin solution (Diluent 1, DiaMed AG,
Cressier-sur-Morat, Switzerland) to detach cells. This enzyme prepara-
tion does not destroy the Rh(D) antigen expressed on Rh-positive red
cells. After two saline washes, a final suspension of cells was prepared in
PBS with 0.3% BSA. Aliquots of this suspension (5  105 cells) were
incubated at RT in the dark for 30 min with the appropriate concentra-
tion (as specified by the manufacturer) of the following fluorescently
conjugated monoclonal antibodies of IgG isotype, anti-CD3-phyco-
erythrin (PE) (Becton Dickinson Co., Mountain View, CA), anti-
CD16-PE (a low-affinity IgG receptor, expressed by granulocytes; Bec-
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ton Dickinson), anti-CD14-PE (an endotoxin receptor on monocytes;
Dako A/S, Glostrup, Denmark), and anti-Rh(D)-PE (Chemicon Austra-
lia, Boronia, Australia). After two washes in PBS, flow cytometric anal-
ysis was performed (Coulter Epics XL-MCL instrument; Beckman
Coulter, Hialeah, FL).
Additional aliquots of islet cells were treated for 30 min at RT with
eithermonoclonal anti-D biotin-conjugated antibody (in-house reagent)
(16), monoclonal anti-CD38 biotin-conjugated (hemopoietic cell mark-
er; Caltag Labs, South San Francisco, CA), or polyclonal antihuman
Ig-biotin conjugated F(ab)2 fragment (custom-made by Silenus Ltd.,
Melbourne, Australia). The cells were washed twice with PBS and, to-
gether with a fourth test sample of cells not exposed to antibody, incu-
bated for 30 min at RT and in the dark with the appropriate quantity of
streptavidin-conjugated PE (Dako A/S, Denmark).
Immunohistochemical analysis
Immunohistochemistry was carried out on fixed islet monolayers,
which had been trypsinized after 2 or 8 d growth in the various sera,
using antibodies to human insulin, glucagon, somatostatin (Dako,
Santa Barbara, CA), or pancreatic polypeptide (Miles,Naperville, IL),
employing the alkaline phosphatase technique. For each preparation,
four samples were stained for the different pancreatic hormones. One
individual scored a total of 500 cells in every section, either positive
or negative, in a blinded fashion. The possibility of a cell staining for
two hormones (e.g. insulin and glucagon) was excluded by double
staining the same sample of cells with different antibodies to distin-
guish the cell types (e.g. horseradish peroxidase for glucagon and
alkaline phosphatase for insulin), as previously described (17). Dou-
ble immunofluorescence staining for insulin (Linco Research, St.
Charles, MO) and Ki67 (GenTex, Carbondale, PA), a cell prolifera-
tion marker, was carried out on unfixed cultures as described (18).
The secondary antibodies were biotinylated antirabbit IgG followed
by fluorescein isothiocyanate-streptavidin (Vector Laboratories, Bur-
lingame, CA) for Ki67 and Texas Red anti-guinea pig IgG (Vector) for
insulin. Images were analyzed by microscopy with Image-Pro Plus
(Media Cybernetics, Inc., Bethesda, MD).
Transmission electron microscopy
Pancreatic islet tissue from two donors was incubated in medium
supplemented with serum 1 at 37 C for 4 d in tissue culture plates,
processed as described (19), and embedded in Spurr’s resin. Ultrathin
sections were stained with uranyl acetate followed by lead citrate.
Statistical analysis
Data are expressed as means  SEM, and paired sample means were
compared using Student’s t test.
Results
Islet cell viability, morphology, and ultrastructure
Pancreatic -cells used in this study had a normal appearance
without damage and contained many secretory vacuoles (Fig.
1A, a). Crystalloids typical of human -cells were present in the
plane of section of many of the secretory
granules. There were no necrotic cells or
other abnormalities in any sample
examined.
Epithelial cells grew from the attached
islets, spreading as a monolayer in a typical
cobblestone configuration. By d 8, the cells
grown in the presence of serum 1 was con-
fluentwith no apparent fibroblasts (Fig. 1A,
b). There were no apparent fibroblasts evi-
dent in any of the cultures examined.
Proliferation and insulin secretion
Monolayers from three separate experi-
ments were stained for the pancreatic endo-
crine hormones insulin, glucagon, somatosta-
tin, and pancreatic polypeptide. Over the 8-d
culture period, the percentage of -cells did
not increase in cultures maintained in normal
human serum but significantly (P 0.01) in-
creased in cultures maintained in serum 1
from64.1 4.1%at d 2 to 74.1 3.2%at d
8and, similarly, in thepresenceof anti-D (P
0.05) from62.34.1%atd2to68.21.1%
at d 8. There was also a significant increase in
the percentage of -cells (P  0.01) within
monolayersmaintained in serum3and serum
4 (P 0.05) but not in the presence of serum
2 or intraglobin F (results not shown). The
numbers of cells staining for the other pancre-
atichormones remainedstaticover theculture
period.The-cell proliferation index, asmea-





FIG. 1. A, Electron micrograph of adult human islet cells from Rh-positive donors cultured in serum 1 for
4 d (a) and light micrograph of monolayer cultures derived from human islets maintained in culture for 8 d
(b). In a, three adjacent -cells are present in the field of view, with the area where their plasma
membranes abut labeled p. Rough endoplasmic reticulum (rer) was present. Some secretory vacuoles had
granules without any crystalloids present in the field of view (g), whereas in others, the section plane
contained crystalloids (c), typical of insulin-containing human -cells (bar, 0.4 m). In b, the cells have a
regular cobblestone appearance (original magnification, 40). B, Ki-67/insulin photomicrographs of
human islet monolayers maintained in culture for 4 d in the presence of anti-D: a, insulin-positive cells; b,
Ki-67-positive cells; c, Ki-67/insulin, double-positive cells (bar, 100 m).
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-cells, for islet cells cultured in anti-D for 4 dwas 87 4.3% (Fig.
1B). Similar results were seen when the anti-D monoclonal anti-
bodies were cocultured with islet cells.
An examination of the effect of increasing concentrations of
anti-D (5–20 g/ml), compared with normal sera, on the prolif-
eration of adult pancreatic islets from Rh-positive donors, re-
vealed that from d 4 of culture, all samples supplemented with
anti-D antibody had shown significant (P  0.01) cell prolifer-
ation (results not shown), and by d 8, concentrations of 15 and
20g/ml anti-D induced a 3-fold increase (P 0.001) of 52.3
0.25 and 54.0  1.0 cpm  103 (n  4), respectively, above
proliferation rates induced by normal serum (17.6 0.5 cpm
103; n 4). There was no significant difference between the cell
proliferation of cells grown in media supplemented with 15
g/ml compared with 20 g/ml anti-D. Similarly, an increased
concentration of anti-D induced a corresponding increase in
chronic insulin secretion by d 8, with the higher concentrations
of anti-D (15 or 20 g/ml) stimulating a 2-fold increase (5.2 
0.1 and 5.4  0.1 pmol insulin/well48 h; n  4), respectively,
comparedwith insulin secretion inducedbynormal serum (1.9
0.1 pmol insulin/well48 h; n 4). Because there was no signif-
icant difference in the proliferation rates or levels of insulin se-
cretion induced by 15 g/ml compared with 20 g/ml anti-D
antibody, 15 g/ml was used in subsequent experiments. Like-
wise, preliminary experiments indicated that 15g/mlwas the
appropriate concentration for the monoclonal antibodies em-
ployed in later experiments.
Figure 2A clearly shows that culture of adult pancreatic islets
in the presence of serum 1 resulted in a significant (P  0.001)
increase in cell proliferation, compared with proliferation stim-
ulated by both serum 2 and normal human serum. By d 8 of
culture, the 4.5-fold increase in cell proliferation was mirrored
by a significant (P  0.001) 4-fold increase in chronic insulin
secretion from the cells (Fig. 2B) compared with normal serum,
indicating that the increase in cell proliferation was likely attrib-
utable to-cell proliferation. This increase in the proliferation of
cells, asmeasured by [3H]thymidine incorporation, was unlikely
to be entirely a result of anti-D because by d 6 and 8 of culture,
the increase in cell number resulting from addition of serum 1
was significantly (P 0.01) higher than that recorded when the
medium was supplemented with 15 g/ml anti-D alone. How-
ever, supplementation of the culture medium with anti-D re-
sulted in a significant (P  0.01) increase in proliferation over
that seen with normal serum alone or with serum 2. Likewise,
whereas the addition of anti-D to the cultures resulted in a sig-
nificant (P  0.001) increase in insulin secretion, the insulin
secretion by cells supplemented with serum 1 was again signif-
icantly (P  0.001) higher than those grown in the presence of
anti-D alone. After 8 d of growth in the four sera, static incu-
bation experiments (Fig. 2C) showed a 3.5-fold response to a
glucose stimulus from islets cultured in all four sera; however,
because cultures supplemented with serum 1 or anti-D had a
larger number of-cells, absolute insulin levelswere higher over-
all (Fig. 2C). Light microscopic examination indicated that the
islet cultures remained healthy and viable throughout.
The proliferation of islet cultures grown in the presence of
serum 3 was significantly (P 0.01) greater from d 4 onwards,
as was cell proliferation in medium supplemented with anti-D
(P  0.001) when compared with normal serum and cells sup-
plemented with intraglobin F (Fig. 3A). From d 6 onward, cell
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FIG. 2. Monolayer cultures of adult human islets from Rh-positive donors
supplemented with patient sera 1 and 2, anti-D Ig (15 g/ml), normal human Ig
(intraglobin F) (15 g/ml), and normal human serum. A, Cell proliferation as
measured by [3H]thymidine incorporation; B, chronic insulin secretion; C,
stimulation by 16.7 mM glucose on the acute regulated release of
immunoreactive insulin. Cells were incubated in basal medium (PBS containing 1
mM CaCl2 and supplemented with 20 mM HEPES and 2 mg/ml BSA, 2.8 mM
glucose) for two consecutive 1-h periods before being exposed to the stimulus
for 1 h; cells in the control group were treated throughout with basal medium.
Results are expressed as the mean  SEM (values represent eight replicates in
each of four separate experiments; SE were very tight in cell proliferation studies
and in some cases are contained within the data point).
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proliferation in cultures supplemented with serum 4 was signif-
icantly (P 0.01) greater than coculture with normal serum and
intraglobin F but remained significantly (P  0.01) less than
proliferation observed serum supplemented with serum 3 and
anti-D (P  0.05) throughout the experiment (Fig. 3A). How-
ever, with regard to chronic insulin secretion (Fig. 3B), by d 8 of
culture, the level of insulin secreted from cultures supplemented
with serum 3 was significantly (P  0.01) higher than from
cultures supplemented with either serum 4 or anti-D (Fig. 3B).
Fromd 6 onward, insulin secretion from cells grown in normal
serum or medium supplemented with intraglobin F was sig-
nificantly (P 0.01) less than other cultures, and by d 8, islets
cocultured with serum 3 secreted three times the amount of
insulin than islets cultured with normal serum. There was no
significant difference in response to an acute glucose challenge
(Fig. 3C). No growth potential was seen when serum either
from normal and pregnant Rh(D)-positive women or from
Rh(D)-negative, non-isoimmunized pregnant women were
used to supplement the islet cell culture medium (results not
shown). No increase in -cell proliferation was seen when
islets from Rh(D)-negative donors were supplemented with
anti-D (Fig. 4).
The proliferation and insulin secretion of islet cultures in the
presence of the anti-D IgG3 monoclonal antibody BRAD-3 was
not significantly different from that seen in thepresenceof anti-D
Ig (Fig. 5). However, both proliferation and insulin secretion in
the presence of the anti-D IgG1monoclonal antibodies BRAD-5
and FOG-1, although significantly (P  0.01) higher than nor-
mal serum, were significantly lower (P  0.01) than BRAD-3-
supplemented cultures from d 6 onward (Fig. 5). As can be seen
from Fig. 6, supplementation of the medium with anti-D Ig or
BRAD-3 did not alter the kinetics of the response curve to in-
creasing glucose concentrations.
Expression of Rh(D) on islet cells
Cultured islet cells did not express CD3, CD14, or CD16
antigens, showing low mean channel fluorescence intensity
(MCF) of 2.8  0.2, 2.8  0.5, and 2.2  0.6, respectively. In
contrast, islet cells treatedwith anti-D showed significantly (P
0.001) higherMCF of 30.2 3.6. These results were confirmed
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FIG. 4. Cell proliferation as measured by [3H]thymidine incorporation of
monolayer cultures of adult human islets from Rh-negative donors supplemented
with anti-D Ig (15 g/ml), normal human Ig (intraglobin F) (15 g/ml), and
normal human serum. Results are expressed as the mean  SEM (values represent
eight replicates in each of four separate experiments; SE were very tight in cell
proliferation studies and in some cases are contained within the data point).
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FIG. 3. Monolayer cultures of adult human islets from Rh-positive donors
supplemented with sera 3 and 4, anti-D Ig (15 g/ml), normal human Ig
(intraglobin F) (15 g/ml), and normal human serum. A, Cell proliferation as
measured by [3H]thymidine incorporation; B, chronic insulin secretion; C,
stimulation by 16.7 mM glucose on the acute regulated release of
immunoreactive insulin. Cells were incubated in basal medium for two
consecutive 1-h periods before being exposed to the stimulus for 1 h; cells in
the control group were treated throughout with basal medium. Results are
expressed as the mean  SEM (values represent eight replicates in each of four
separate experiments; SE were very tight in cell proliferation studies and in
some cases are contained within the data point).
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via the indirect method of using a biotinylated antibody in the
first step followed by a second incubation with streptavidin-PE
to incorporate the fluorescent dye. Only the biotinylated mono-
clonal anti-D followed by streptavidin-PE showed strongly pos-
itive MCF (60.4  9.7), whereas the two other biotinylated Igs
[normal pooled human Ig, F(ab)2 fragment and mouse anti-
CD38] gave results not significantly different from the MCF
obtained with streptavidin-PE alone (4.0  0.6).
Discussion
The hypothesis that fetal hyperinsulinism associatedwith Rh(D)
isoimmunization might be a direct consequence of the induction
of up-regulated islet cell activity by trans-placentally acquired
maternal anti-D antibody was supported by the results of our in
vitro study of human islet cells in the presence of sera from iso-
immunized mothers. Similar up-regulation of both islet cell pro-
liferation and insulin secretion by the cells were obtained after
their exposure to anti-D Ig and specific Rh(D) monoclonal an-
tibodies (9, 10) but not after exposure to control human Ig.
However, serum 1 [collected from an Rh(D)-negative mother,
whose infant was confirmed to be Rh(D) positive, DAT positive,
and jaundiced and had both hypoglycemia and hyperinsulin-
emia], resulted in significantly (P  0.001) higher cell prolifer-
ation and chronic insulin secretion when compared with cells
grown in media supplemented with anti-D antibody alone. It is
possible that some synergistic effect with other serum compo-
nents, such as growth factors and cytokines, like TGF-, which
is induced byRh-immune globulin (20), may have accounted for
the observed results. It was also noted that the augmented islet
cell activity behaved physiologically in that further enhancement
of insulin secretion occurred upon exposure to an elevated glu-
cose concentration, demonstrating that the increased cell divi-
sion did not induce autonomous behavior in the treated islet cell
population, with no sign of disordered glucose metabolism in
glucose response data or dysmorphic changes in the islet cells,
other than the exaggerated proliferation. The cultures remained
viable and healthy throughout, and the number of -cells in-
creased significantly over the 8-d period in the presence of sera
1, 3, 4, and anti-D. The double Ki67 and insulin immunofluo-
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FIG. 5. Monolayer cultures of adult human islets from Rh-positive donors
supplemented with anti-D Ig, anti-D monoclonal antibodies BRAD-3, BRAD-5,
and FOG-1 (15 g/ml), and normal human serum. A, Cell proliferation as
measured by [3H]thymidine incorporation; B, chronic insulin secretion; C,
stimulation by 16.7 mM glucose on the acute regulated release of
immunoreactive insulin. Results are expressed as the mean  SEM (values
represent eight replicates in each of four separate experiments; SE were very tight
in cell proliferation studies and in some cases are contained within the data
point).
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FIG. 6. Monolayer cultures of adult human islets from Rh-positive donors
supplemented with anti-D Ig, anti-D monoclonal antibody BRAD-3 (15 g/ml),
and normal human serum. Dose-response curve to varying concentrations of
glucose (0–20 mM). Results are expressed as the mean  SEM (values represent
eight replicates in each of four separate experiments; SE were very tight in cell
proliferation studies and in some cases are contained within the data point).
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rescent staining confirmed that anti-D stimulated proliferation
of-cells and discounts the likelihood that the increase in insulin
secretion was due to any extraneous factors. The fact that islet
cell samples isolated from Rh(D)-negative human donors were
unresponsive to exposure to anti-D Ig or maternal sera contain-
ing anti-D further supports our hypothesis that isoimmunization
may induce islet cell proliferation.
The growth-stimulating effect of Rh(D) antibody in vitrowas
likely a consequence of the presence and/or binding of anti-D Ig
at the cell surface. The Rh(D) antigen is not only expressed on
erythrocytes but has also been described in other tissues from
Rh(D)-positive individuals (21), although this is believed to be
the first report of islet cells expressing the antigen. It is not sur-
prising that the IgG3monoclonal BRAD-3wasmore effective in
stimulating -cell proliferation than the IgG1 monoclonals, be-
cause BRAD-3 has been shown in other studies to be more ef-
fective than IgG1 monoclonal antibodies in the clearing of
Rh(D)-positive red cells (9, 10). The implication that the Rh
glycoproteins are specific ammonium transporters may have
some bearing on the observed proliferation of -cells in the pres-
ence of anti-D, although RhD expression itself has not been im-
plicated in such transport mechanisms in erythroid cells (22).
Aside from the possible associated problems of the wide-
spread use of immunosuppressive drugs and other questions
about impaired glucose tolerance (23, 24), the main obstacle for
widespread islet transplantation for type I diabetes is scarcity of
donors. Various growth factors have been reported to expand
islet cell mass in vitro and in vivo, such as PTH-related protein
(25), hepatocyte growth factor (26), prolactin (27), and IGF-I
and -II (28, 29). In several studies, the proliferation of islet cells
has been linked to the division of ductal cells (29, 30), which lose
their specific duct phenotypewithproliferation, resulting inmul-
tipotent cells that can subsequently differentiate into islet cells, in
the presence of appropriate external stimuli, over a periodof 3–4
wk (30). However, the proliferation of insulin-secreting, glu-
cose-responsive tissue in this study occurred from 4 d onward
and therefore may be indicative of proliferation of the original
-cell mass. Evidence from other studies has shown that ter-
minally differentiated -cells retain a proliferative capacity
that is recognized as an important regulator of the adult -cell
mass (31–33).
Although preliminary, the results of this study suggest the
presence of a factor in maternal serum containing a hemolytic
anti-D antibody that exerts growth-stimulating effects on iso-
lated primary human islet cells. Similar responses were observed
after culture in medium containing the human anti-D Ig and
specific anti-D monoclonal antibodies. Such monoclonal anti-
bodies directed against a specific Rh(D) epitope may be ulti-
mately developed for future therapeutic use.
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